Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 16, Issue 4, Pages 241-263Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd.2016.256
Keywords
-
Funding
- US National Cancer Institute
- Breast Cancer Research Foundation
- S.G. Komen for the Cure
- BRCA Foundation
Ask authors/readers for more resources
In the past few years, it has become clear that mutations in epigenetic regulatory genes are common in human cancers. Therapeutic strategies are now being developed to target cancers with mutations in these genes using specific chemical inhibitors. In addition, a complementary approach based on the concept of synthetic lethality, which allows exploitation of loss-of-function mutations in cancers that are not targetable by conventional methods, has gained traction. Both of these approaches are now being tested in several clinical trials. In this Review, we present recent advances in epigenetic drug discovery and development, and suggest possible future avenues of investigation to drive progress in this area.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available